<DOC>
	<DOCNO>NCT00215917</DOCNO>
	<brief_summary>N-methyl-D-aspartate receptor ( NMDAR ) agonist , add classical atypical antipsychotic medication , reduce negative , depressive , cognitive symptomatology . We investigate effect D-serine , ( DSR ) , selective potent NMDAR agonist , monotherapy treatment resistant schizophrenic . 40 subject stable dos risperidone randomize double-blind condition treatment group , receive D-serine 2100 mg , control group , continue receive risperidone . Treatment continue 14 week . Symptoms side effect rat biweekly CGI , PANSS , BPRS , SAS , AIMS , UKU . Before trial subject undergo neuropsychological assessment . Baseline post-trial level amino acid relevant glutamatergic neurotransmission ( glutamate , glutamine , aspartate , glycine , serine , alanine ) assess . The primary outcome measure study PANSS total score positive negative symptom cluster score .</brief_summary>
	<brief_title>D-Serine Monotherapy Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . DSMIV criterion chronic schizophrenia 2 . Treatment resistant 3. aged 1870 4 . Two month stable risperidone dose 5 . PANSS positive symptom cluster score &gt; 20 6 . PANSS negative symptom cluster score &gt; 22 1 . Substance abuse 2 . Concurrent DSM IV axis I disorder 3 . Serious medical disorder 4 . Concurrent drug therapy obscure effect risperidone DSR .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>NMDA</keyword>
	<keyword>D-serine</keyword>
</DOC>